LON:INS Instem (INS) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Instem Stock (LON:INS) 30 days 90 days 365 days Advanced Chart Get Instem alerts:Sign Up Key Stats Today's Range N/A50-Day Range 830▼ 83052-Week Range N/AVolume3,800 shsAverage Volume85,542 shsMarket Capitalization£199.62 millionP/E Ratio5,928.57Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewInstem plc, together with its subsidiaries, provides information technology solutions and services to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Blur Clinical Annonymization; Logbook ELN, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a windows-based system for non-clinical evaluation studies. In addition, it provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; KnowledgeScan Target Safety Assessment services; SENDTrial, a web based solution that can be accessed through a subscription; and Predict delivers computational models. Further, the company provides Sorcerer Colony Counter; sales and administrative support; training, validation, consultancy, cloud, and safety assessment and regulatory information management software services; software solutions to extract intelligence from research and development related healthcare data; and holds intellectual property rights and investment. It also develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.Read More… Receive INS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Instem and its competitors with MarketBeat's FREE daily newsletter. Email Address INS Stock News Headlines‘Biotech shaping future economy, public health’: Union Minister Jitendra SinghApril 25, 2025 | msn.comScientists achieve breakthrough in gene therapy for haemophiliaApril 24, 2025 | msn.comMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.May 2, 2025 | Stansberry Research (Ad)Instem Strengthens Commitment to End-to-End Preclinical Platform Amid Regulatory EvolutionApril 17, 2025 | finance.yahoo.comMarc Berger Joins Wilson Sonsini’s General Counsel in Residence ProgramApril 10, 2025 | morningstar.comMarc Berger Joins Wilson Sonsini's General Counsel in Residence ProgramApril 9, 2025 | tmcnet.comInstem Introduces Cloud-Hosted Non-GLP Pathology Module for ProvantisJanuary 9, 2025 | finance.yahoo.comLeadership Transition at the National Science and Technology Medals Foundation (NSTMF)December 6, 2024 | tmcnet.comSee More Headlines INS Stock Analysis - Frequently Asked Questions How do I buy shares of Instem? Shares of INS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Instem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Instem investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), IQE (IQE) and Omega Diagnostics Group (ODX). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolLON:INS CIKN/A Webwww.instem.com Phone+44-1785-825600FaxN/AEmployees500Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX 0.14 Trailing P/E Ratio5,928.57 Forward P/E RatioN/A P/E Growth1.89Net Income£3.34 million Net Margins5.50% Pretax MarginN/A Return on Equity6.35% Return on Assets4.62% Debt Debt-to-Equity Ratio3.47 Current Ratio0.95 Quick Ratio0.84 Sales & Book Value Annual Sales£61.63 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow15.25 Book ValueGBX 239 per share Price / BookN/AMiscellaneous Outstanding Shares24,050,000Free FloatN/AMarket Cap£199.62 million OptionableNot Optionable Beta0.42 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (LON:INS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instem plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Instem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.